Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Annexon, Inc. (Nasdaq: ANNX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, including current reports, registration statements and other disclosures related to its complement-focused neuroinflammation platform. Annexon is a clinical-stage biopharmaceutical company developing C1q- and classical complement-targeted therapies for neuroinflammatory and complement-mediated diseases of the body, brain and eye.
Through this page, readers can review Annexon’s Form 8-K current reports, which have included announcements of quarterly financial results, portfolio progress and material changes affecting security holders, such as amendments to common stock purchase warrants. Filings related to public offerings of common stock and pre-funded warrants are made under an effective Form S-3 shelf registration statement, with prospectus supplements detailing the terms of each offering.
As Annexon advances late-stage programs such as tanruprubart in Guillain-Barré syndrome and vonaprument in geographic atrophy, investors may also monitor future annual reports on Form 10-K, quarterly reports on Form 10-Q and additional 8-K filings for updates on clinical development, cash runway and risk factors. Any insider transactions by officers and directors would be reported on Form 4 and can be reviewed alongside these company-level filings.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points, explain technical language and help users quickly understand the implications of new filings. Real-time updates from EDGAR ensure that new Annexon filings appear promptly, while AI-generated overviews of 10-K, 10-Q and 8-K reports, as well as insider trading forms, support more efficient analysis of the company’s regulatory and financial disclosures.
William H. Carson, a director of Annexon, Inc. (ANNX), purchased 4,115 shares of the company’s common stock on 09/30/2025 at a weighted average price of $3.05 per share under a Rule 10b5-1 trading plan adopted on March 17, 2025. After the reported purchase, the filing shows the reporting person beneficially owned 42,060 shares. The filing states the trades executed at prices ranging from $3.035 to $3.08, and the reporting person offers to provide details of the per-trade quantities on request. The transaction was reported on a Form 4 as required for Section 16 reporting.
William H. Carson, a director of Annexon, Inc. (ANNX), purchased 4,115 shares of the company's common stock on 09/02/2025 at a weighted average price of $2.09 per share. The shares were bought under a Rule 10b5-1 trading plan adopted March 17, 2025, through multiple trades priced between $2.06 and $2.115.
Following the transaction, the reporting person beneficially owned 37,945 shares. The filing reports the purchase as a planned, rule-compliant acquisition rather than an opportunistic trade.
Annexon, Inc. is a clinical-stage biopharma with no approved products and significant historical losses. The company is advancing three lead programs: tanruprubart for Guillain-Barré Syndrome (GBS), which showed rapid and sustained functional improvement in a placebo-controlled Phase 3 trial and has Fast Track and orphan designations and a planned MAA submission in Europe in Q1 2026; vonaprument for geographic atrophy (GA), the only GA candidate to show significant vision preservation in Phase 2, with ARCHER II enrollment completed at 659 patients and topline data expected in H2 2026; and ANX1502, an oral C1s inhibitor with supportive Phase 1 PK/PD data and ongoing proof-of-concept study in cold agglutinin disease. The filing discloses recent equity offerings including pre-funded warrants (examples: 7,000,000 and 18,379,861 pre-funded warrants referenced) and ESPP availability of 2,959,996 shares. The company warns it will require substantial additional financing, relies on third-party manufacturers and collaborators, faces extensive regulatory and clinical risks, and has governance provisions that may limit stockholder control.
Annexon, Inc. Schedule 13G/A (Amendment No. 1) discloses that Logos Global entities and William Arsani filed jointly regarding Annexon common stock (CUSIP 03589W102) related to a reportable event dated 06/30/2025. The filing identifies five reporting persons: Logos Global Management LP, Logos Global Management GP LLC, Logos Global Master Fund LP, Logos GP LLC, and Arsani William, and provides the filer address at One Letterman Drive, Building C, Suite C3-350, San Francisco, CA 94129.
The statement states each reporting person beneficially owns 0 shares representing 0% of the class, with zero sole or shared voting or dispositive power. The reporting persons say they file jointly but disclaim membership in a group and disclaim beneficial ownership except to the extent of any pecuniary interest. The filing is signed by Arsani William on 08/13/2025.
Filing: Schedule 13G/A (Amendment No. 3) reporting beneficial ownership in Annexon Inc. (ANNX) as of 06/30/2025; signature dated 08/05/2025.
Key facts
- Reporting persons: FMR LLC and Abigail P. Johnson.
- Aggregate beneficial ownership: 15,695,226.36 shares, representing 14.3% of the class.
- Voting/dispositive powers reported: FMR LLC sole voting power 15,690,765.00; sole dispositive power 15,695,226.36; shared powers 0.00; Abigail P. Johnson reports sole dispositive power 15,695,226.36; no voting power.
Certification: Signatory certifies the securities are held in the ordinary course of business and not to change or influence control of the issuer. Exhibit 99 and Exhibit 24 references included.
Annexon, Inc. (NASDAQ: ANNX) filed a Form 144 disclosing a proposed insider sale of up to 853 common shares, valued at approximately $2,226.42. The shares, representing roughly 0.0008% of the 109.7 million shares outstanding, were acquired through restricted-stock vesting on 07 Jul 2025 and are slated for sale on or about 14 Jul 2025 via Fidelity Brokerage Services LLC on the NASDAQ exchange.
No other sales by the filer in the past three months were reported, and the filing contains the standard affirmation that the seller possesses no undisclosed material adverse information. Filer name and relationship to the issuer were not provided, suggesting an administrative notice rather than a significant ownership change.
Given the minimal share count and dollar value, this transaction is considered routine and unlikely to affect Annexon’s capital structure, liquidity, or share price. Investors typically view such small-scale Form 144 filings as non-material disclosures.
Annexon, Inc. (ANNX) has filed a Form 144 indicating the planned sale of 1,117 common shares through Fidelity Brokerage Services on 14 July 2025. The shares, valued at an aggregate $2,880.97, were acquired via restricted-stock vesting on 11 July 2025 as compensation. Outstanding shares total 109,714,404; therefore, the proposed sale represents roughly 0.001% of shares outstanding, a de-minimis amount that will not affect float or control. No other sales have occurred in the past three months, and the filer affirms no undisclosed material adverse information.